tumor mutational burden
Predicting PD-1 checkpoint inhibitor sensitivity in prostate cancer: potential molecular biomarkers
How can we continue the success of checkpoint inhibitors for bladder cancer treatment?
Tumor mutational burden (TMB): a predictive biomarker for lung cancer immunotherapy response
How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?